[
  {
    "ts": null,
    "headline": "Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know",
    "summary": "Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=8a2d688b069f887ae9f8826940c9472a35da067cd9d1e2c79f0e04da063c8bfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750974604,
      "headline": "Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know",
      "id": 135576848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=8a2d688b069f887ae9f8826940c9472a35da067cd9d1e2c79f0e04da063c8bfc"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s RSV shot for infants gets key approval despite RFK Jr.’s panel shakeup",
    "summary": "Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.",
    "url": "https://finnhub.io/api/news?id=5bb28cae1334fa4f6f0efbc4d2acd4485b27ecf1ba49b9408da530845fa0220f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750960477,
      "headline": "Merck’s RSV shot for infants gets key approval despite RFK Jr.’s panel shakeup",
      "id": 135617544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.",
      "url": "https://finnhub.io/api/news?id=5bb28cae1334fa4f6f0efbc4d2acd4485b27ecf1ba49b9408da530845fa0220f"
    }
  },
  {
    "ts": null,
    "headline": "ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season",
    "summary": "RAHWAY, N.J., June 26, 2025--ACIP Recommends Merck’s ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season",
    "url": "https://finnhub.io/api/news?id=d582b2f28314c77042a2b983725dd2cab75556a4a9c9dac18f09e0c281f69450",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750959540,
      "headline": "ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season",
      "id": 135576849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 26, 2025--ACIP Recommends Merck’s ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season",
      "url": "https://finnhub.io/api/news?id=d582b2f28314c77042a2b983725dd2cab75556a4a9c9dac18f09e0c281f69450"
    }
  },
  {
    "ts": null,
    "headline": "Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus",
    "summary": "Merck announced the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices voted to recommend ENFLONSIA?? as an option for the prevention of respiratory...",
    "url": "https://finnhub.io/api/news?id=1cb92392ec14d86c7043aad818384946da24968e8718e6466137c40655106705",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750951253,
      "headline": "Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus",
      "id": 135564035,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced the U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices voted to recommend ENFLONSIA?? as an option for the prevention of respiratory...",
      "url": "https://finnhub.io/api/news?id=1cb92392ec14d86c7043aad818384946da24968e8718e6466137c40655106705"
    }
  },
  {
    "ts": null,
    "headline": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
    "summary": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
    "url": "https://finnhub.io/api/news?id=d9355b04643df5347e9fc158fec2387c4041b7cf91cb73ecf64d3625aeefa72c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750948080,
      "headline": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
      "id": 135593337,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee",
      "url": "https://finnhub.io/api/news?id=d9355b04643df5347e9fc158fec2387c4041b7cf91cb73ecf64d3625aeefa72c"
    }
  },
  {
    "ts": null,
    "headline": "Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?",
    "summary": "Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.",
    "url": "https://finnhub.io/api/news?id=82caef34d94f32b3dd4e2cccb04b68afc051612e59d764ccd1f6e778a3ea7d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750945620,
      "headline": "Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?",
      "id": 135560053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.",
      "url": "https://finnhub.io/api/news?id=82caef34d94f32b3dd4e2cccb04b68afc051612e59d764ccd1f6e778a3ea7d44"
    }
  },
  {
    "ts": null,
    "headline": "Europe Proteomics Research Report 2025: Market Insights, Competitive Landscape and Forecasts 2024-2034 Featuring Biognosys, DiaSorin, Merck, Oxford Expression Technologies",
    "summary": "The Europe proteomics market is expected to rise to $27.43 billion by 2034 from $8.77 billion in 2024, with a CAGR of 12.07%. Driving this growth are advancements in mass spectrometry and next-gen sequencing technologies enhancing protein analysis precision. The increased focus on personalized healthcare, catalyzed by biomarker discovery and disease profiling, amplifies demand. Support from EU funding, public-private partnerships, and strategic alliances further propels market expansion. Europe'",
    "url": "https://finnhub.io/api/news?id=c16ea9edb6663834395f545fda696245d9a17038bdeb182e322751a490aee0ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750943460,
      "headline": "Europe Proteomics Research Report 2025: Market Insights, Competitive Landscape and Forecasts 2024-2034 Featuring Biognosys, DiaSorin, Merck, Oxford Expression Technologies",
      "id": 135558760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Europe proteomics market is expected to rise to $27.43 billion by 2034 from $8.77 billion in 2024, with a CAGR of 12.07%. Driving this growth are advancements in mass spectrometry and next-gen sequencing technologies enhancing protein analysis precision. The increased focus on personalized healthcare, catalyzed by biomarker discovery and disease profiling, amplifies demand. Support from EU funding, public-private partnerships, and strategic alliances further propels market expansion. Europe'",
      "url": "https://finnhub.io/api/news?id=c16ea9edb6663834395f545fda696245d9a17038bdeb182e322751a490aee0ce"
    }
  },
  {
    "ts": null,
    "headline": "US CDC panel broadly recommends flu shots free from thimerosal",
    "summary": "The external committee advising theU.S. Centers for Disease Control and Prevention on vaccinepolicy voted that all adults in the country receive a seasonalflu shot in single-dose forms that are...",
    "url": "https://finnhub.io/api/news?id=09551043df1991b46da75cb76127114df52a438d72eaa9161c061bf4bb5b541c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750942747,
      "headline": "US CDC panel broadly recommends flu shots free from thimerosal",
      "id": 135560663,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The external committee advising theU.S. Centers for Disease Control and Prevention on vaccinepolicy voted that all adults in the country receive a seasonalflu shot in single-dose forms that are...",
      "url": "https://finnhub.io/api/news?id=09551043df1991b46da75cb76127114df52a438d72eaa9161c061bf4bb5b541c"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's US vaccine panel backs preservative-free shot despite safety evidence",
    "summary": "U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans receive seasonal influenza shots that are free from the mercury-based...",
    "url": "https://finnhub.io/api/news?id=ad41e594ff6ec02e20efe768891d62fd2931b9fe32ddcb86a2fd29070427234d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750934956,
      "headline": "Kennedy's US vaccine panel backs preservative-free shot despite safety evidence",
      "id": 135565855,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans receive seasonal influenza shots that are free from the mercury-based...",
      "url": "https://finnhub.io/api/news?id=ad41e594ff6ec02e20efe768891d62fd2931b9fe32ddcb86a2fd29070427234d"
    }
  },
  {
    "ts": null,
    "headline": "2 Stocks Too Cheap to Ignore at These Prices",
    "summary": "Alphabet can overcome legal headwinds and continue to perform well in the long term.  Merck should be able to remain a leader in oncology despite mounting competition.  Let's consider two stocks that meet these criteria: Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Merck (NYSE: MRK).",
    "url": "https://finnhub.io/api/news?id=979b4281ecfdcb7db21c3d57d0cdc80865256747cc8d3e341e33b072eb46196a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750934700,
      "headline": "2 Stocks Too Cheap to Ignore at These Prices",
      "id": 135552940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Alphabet can overcome legal headwinds and continue to perform well in the long term.  Merck should be able to remain a leader in oncology despite mounting competition.  Let's consider two stocks that meet these criteria: Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), and Merck (NYSE: MRK).",
      "url": "https://finnhub.io/api/news?id=979b4281ecfdcb7db21c3d57d0cdc80865256747cc8d3e341e33b072eb46196a"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's new US vaccine panel backs thimerosal-free flu vaccines",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend Americans receive seasonal influenza shotsthat are free from the mercury-based...",
    "url": "https://finnhub.io/api/news?id=4326ef8f07aa1f2a8d45a9243d8115984ca28b21a526c7946f13f067ea1e7c14",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750929378,
      "headline": "Kennedy's new US vaccine panel backs thimerosal-free flu vaccines",
      "id": 135560958,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend Americans receive seasonal influenza shotsthat are free from the mercury-based...",
      "url": "https://finnhub.io/api/news?id=4326ef8f07aa1f2a8d45a9243d8115984ca28b21a526c7946f13f067ea1e7c14"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's new US vaccine panel backs Merck's RSV drug for infants",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend use of Merck's recently approvedRSV antibody drug for infants 8 months or younger...",
    "url": "https://finnhub.io/api/news?id=5f6af8d12ac5476228ffb0d1ca3fec3808ff9e72034bb2ac6c427f827badd0e5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750929378,
      "headline": "Kennedy's new US vaccine panel backs Merck's RSV drug for infants",
      "id": 135560250,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday to recommend use of Merck's recently approvedRSV antibody drug for infants 8 months or younger...",
      "url": "https://finnhub.io/api/news?id=5f6af8d12ac5476228ffb0d1ca3fec3808ff9e72034bb2ac6c427f827badd0e5"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's US vaccine panel votes in favor of Merck's RSV antibody drug",
    "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday for recommending use of Merck's RSV antibodydrug for infants 8 months or younger whose mothers...",
    "url": "https://finnhub.io/api/news?id=18eed9cdeeebad5ca23a1d96239571c7b911fe9aee14a7a333b23b875801a87d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750929378,
      "headline": "Kennedy's US vaccine panel votes in favor of Merck's RSV antibody drug",
      "id": 135559272,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "U.S. Health Secretary Robert F.Kennedy Jr.'s newly revamped vaccine advisory panel voted onThursday for recommending use of Merck's RSV antibodydrug for infants 8 months or younger whose mothers...",
      "url": "https://finnhub.io/api/news?id=18eed9cdeeebad5ca23a1d96239571c7b911fe9aee14a7a333b23b875801a87d"
    }
  },
  {
    "ts": null,
    "headline": "US CDC panel votes in favor of Merck's RSV antibody drug",
    "summary": "An advisory panel of the U.S.Centers for Disease Control and Prevention on Thursdayrecommended the use of Merck's respiratory syncytialvirus therapy, Enflonsia, for infants 8 months or younger,...",
    "url": "https://finnhub.io/api/news?id=e3434b157a1d92a0230d3b9c7dd6e90ec83697503968adb49f6b91cf18986ab1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750929378,
      "headline": "US CDC panel votes in favor of Merck's RSV antibody drug",
      "id": 135558012,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "An advisory panel of the U.S.Centers for Disease Control and Prevention on Thursdayrecommended the use of Merck's respiratory syncytialvirus therapy, Enflonsia, for infants 8 months or younger,...",
      "url": "https://finnhub.io/api/news?id=e3434b157a1d92a0230d3b9c7dd6e90ec83697503968adb49f6b91cf18986ab1"
    }
  }
]